Capricor: Further Value Unlocked With Priority Review Of Deramiocel
Portfolio Pulse from
Capricor Therapeutics' Deramiocel has received FDA Priority Review for treating DMD Cardiomyopathy, with a PDUFA target date of August 31, 2025. This could be the first FDA-approved drug for this condition, offering hope to patients with no current treatment options.
March 04, 2025 | 9:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Capricor Therapeutics' Deramiocel has received FDA Priority Review for DMD Cardiomyopathy, potentially becoming the first approved treatment for this condition. The PDUFA target date is August 31, 2025.
The FDA Priority Review for Deramiocel is a significant milestone for Capricor Therapeutics, as it could lead to the first approved treatment for DMD Cardiomyopathy. This regulatory progress is likely to positively impact CAPR's stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100